Trial Profile
Thorough QT/QTc Study to Assess the Electrocardiographic Safety of a New Gadolinium-based Contrast Agent P03277 in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Apr 2020
Price :
$35
*
At a glance
- Drugs Gadopiclenol (Primary) ; Moxifloxacin
- Indications CNS disorders; Liver cancer
- Focus Adverse reactions
- Sponsors Guerbet
- 17 Apr 2020 Results assessing effect of gadopiclenol on the QTc interval in healthy subjects, published in the British Journal of Clinical Pharmacology
- 11 Jul 2019 Status changed from active, no longer recruiting to completed.
- 11 Sep 2018 New trial record